Explore mission critical vaccine development updates

The recent H1N1 flu pandemic has further illustrated the necessity to quickly develop vaccines in response to a global health crisis. The Vaccines Development Forum has added all new content to address rapid vaccine product in response to the world’s current pandemic. Explore the most mission critical updates and advances in the H1N1 flu vaccine rapid development with case studies and expertise from The National Institute of Health, GlaxoSmithKline, Vical, and CSL Limited.

Register today to get real time access to the industry’s response to the latest global health crisis and cutting-edge case studies on developing innovative and profitable vaccines to shave years off of your vaccine development timelines.

To connect with more professionals in the Vaccines field, join our Vaccines Development Forum Group on LinkedIn or join us in Boston September 23-25 for the Vaccines Development Forum.

Share this article with your social network, just click below to share now!

Share |

Vical's H1N1 vaccines tested

According to SignOnSanDiego.com, Vical has tested their H1N1 flu vaccines on animals, and found the tests to be successful. Their delivery method is unique, injecting genetic material, such as DNA or RNA, that expresses a protein that induces an immune response. This method is successful on animals, but has not yet been marketed for humans.

The Vaccines Development Forum has released their updated agenda, which includes new sessions that will specifically discuss how the vaccines field is responding to the need of rapid vaccine development for the H1N1 vaccine. Check out the PDF here.

To connect with more professionals in the Vaccines field, join our Vaccines Development Forum Group on LinkedIn or join us in Boston September 23-25 for the Vaccines Development Forum.

Share this article with your social network, just click below to share now!

Share |